The management of Hodgkin disease in the young child. Curr Opin Pediatr 2003 Feb;15(1):10-6
Date
01/25/2003Pubmed ID
12544266DOI
10.1097/00008480-200302000-00003Scopus ID
2-s2.0-0037305984 (requires institutional sign-in at Scopus site) 30 CitationsAbstract
Although childhood Hodgkin disease is sensitive to the treatment regimens devised for Hodgkin disease in adults, long-term toxicity is enhanced in the developing individual. As a result, there have been dual goals in the design of clinical trials for pediatric Hodgkin disease: 1) to reduce long-term organ injury; and 2) to increase efficacy. Radiation dose and field has been reduced by enhanced reliance on chemotherapy, thus limiting the risks of hypoplasia, hypothyroidism, secondary cancers, and valvular and atherosclerotic heart disease. Multiagent, chemotherapeutic regimens for children have been developed to avoid the risks of sterility, leukemia, and cardiopulmonary toxicity. Newer approaches advocate for early dose intensity to limit cumulative therapy using response-based paradigms. Targeting molecular mechanisms specific for the Reed-Sternberg cell may allow for less toxic and more efficacious treatments in the future.
Author List
Schwartz CLAuthor
Cindy L. Schwartz MD, MPH Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Age Factors
Antineoplastic Agents
Child
Dose-Response Relationship, Drug
Dose-Response Relationship, Radiation
Hodgkin Disease
Humans
Time Factors
